Thrombus formed in blood vessel is a progressive process, which would lead to life-
threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the …

Tissue plasminogen activator (tPA) is the only FDA approved medical treatment for the
ischaemic stroke. However, it associates with some inevitable limitations, including: short …

Conventional thrombolytic drugs for vascular blockage such as tissue plasminogen activator
(tPA) are challenged by the low bioavailability, off-target side effects and limited penetration …

Thrombotic occlusion of the coronary artery, which triggers acute myocardial infarction, is
one of the major causes of death in the USA. Currently, arterial occlusions are treated with …

Ischemic stroke is one of the major causes of severe disability and death worldwide. It is
mainly caused by a sudden reduction in cerebral blood flow due to obstruction of the …

Globally, the incidence of thromboembolic diseases has increased in recent years,
accompanied by an increase in patient mortality. Currently, several targeting delivery …

Thrombolytic agents have thus far yielded limited therapeutic benefits in the treatment of
thrombotic disease due to their short half-life, low targeting ability, and association with …

Objectives: The purpose of this study was to develop a new intelligent drug delivery system
for intracoronary thrombolysis with a strong thrombolytic effect without increasing bleeding …

Fibrinolytic drugs have been successfully used to manage acute thrombotic and
thromboembolic conditions. However, their narrow administration time window, rapid …

Various plasminogen activators have been routinely used for the treatment of thrombotic
diseases. However, these agents possess various problems eg short half life and other …